The Chosun Ilbo on MSN
FDA Speeds Up Custom Gene Therapy Approvals With Existing Data
Last May, people were thrilled to learn that a 7-month-old baby who became the first in the world to receive a personalized ...
Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...
Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...
The FDA plans to introduce a faster approval process for custom gene-editing therapies, allowing combined trials for patients with related rare ...
The stock of biotechnology firm Intellia Therapeutics has experienced a severe downturn after US regulators imposed a ...
Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...
Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...
The clinical hold follows Intellia's disclosure that it paused dosing in two Phase III trials after a patient experienced a serious adverse event.
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that makes a longer halt more likely.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback